4Basebio (4BB.L) Osake Kurssi

4basebio Plc develops advanced therapy medicinal products using synthetic DNA and non-viral delivery platforms for cell and gene therapies, DNA vaccines, and mRNA solutions. The company manufactures application-specific synthetic DNA for research, therapeutic, and pharmacological use, while also creating non-viral vectors for efficient payload delivery. Its technology enables the production of synthetic DNA constructs, mRNA, and vectors for cell and tissue-specific delivery, targeting applications such as AAV and Lentivirus viral vectors, mRNA vaccines, genome editing, and DNA vaccines. The company focuses on exploiting intellectual property in cell and gene therapies and DNA vaccines to drive innovation and commercialization. The primary customers for 4basebio Plc's products include research institutions, biotechnology firms, and pharmaceutical companies seeking advanced therapeutic solutions. These entities purchase synthetic DNA constructs, non-viral delivery vectors, and specialized DNA-based products for use in developing cell and gene therapies, DNA vaccines, and mRNA therapeutics. The company's offerings are tailored to support the development of safe and effective treatments across multiple therapeutic areas. 4basebio Plc's revenue streams are derived from the manufacturing and supply of synthetic DNA products, non-viral delivery platforms, and intellectual property licensing. The company generates income through the sale of application-specific synthetic DNA for research and therapeutic applications, as well as the development of delivery vectors for targeted therapies. By leveraging its proprietary technology in DNA synthesis and payload delivery, 4basebio Plc positions itself as a key provider of essential components for next-generation biologics and vaccines.